Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MGLL | Q99685 | 4/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4952666 | 0.90 | PTGS1 (0.65) | PTGS1PTGS2ALDH1A1PKMMAPK1 | |
| SCHEMBL2111664 | 0.87 | PTGS1 (0.76) | PTGS1PTGS2ALDH1A1PKMMAPK1 | |
| SCHEMBL15391717 | 0.85 | PTGS1 (0.70) | PTGS1PTGS2ALDH1A1PKMMAPK1 | |
| SCHEMBL34464 | 0.85 | PTGS1 (0.70) | PTGS1PTGS2ALDH1A1PKMMAPK1 | |
| Hydrochloric Acid SCHEMBL25414956 | 0.83 | PTGS1 (0.68) | PTGS1PTGS2ALDH1A1PKMMAPK1 | |
| SCHEMBL28981238 | 0.83 | PTGS1 (0.68) | PTGS1PTGS2ALDH1A1PKMMAPK1 | |
| SCHEMBL1055378 | 0.82 | TSHR (0.43) | PTGS1PTGS2ALDH1A1MGLLNPSR1 | |
| Hydrazine SCHEMBL20561226 | 0.81 | PTGS1 (0.66) | PTGS1PTGS2ALDH1A1PKMMAPK1 | |
| Succinimide SCHEMBL28182577 | 0.79 | PTGS1 (0.54) | PTGS1PTGS2ALDH1A1PKMMAPK1 | |
| Succinic Acid SCHEMBL28916613 | 0.79 | LMNA (0.45) | ALDH1A1PKMMAPK1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119654167-A | Nucleic acid compositions comprising amphiphilic oligoethylene glycol (OEG) conjugated compounds and methods of using such compounds and compositions | 生物技术公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-118852331-A | Chemical conjugates of Evan's blue derivatives and their use as radiation therapies and imaging agents for targeting prostate cancer | 美国政府健康及人类服务部 | 2024-10-29 | — | — | CN | disclosed |
| CN-111741751-B | Chemical conjugates of Evan's blue derivatives and their use as radiation therapies and imaging agents for targeting prostate cancer | 美国政府健康及人类服务部 | 2024-06-28 | — | — | CN | disclosed |
| CN-111558049-B | Methylene carbamate linkers for use with target-drug conjugates | 西雅图基因公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-111569086-B | Methylene carbamate linkers for use with target-drug conjugates | 西雅图基因公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20240092932-A1 | MONOCLONAL IGM ANTIBODIES FROM ENTIRELY CARBOHYDRATE CONSTRUCTS | THE UNIVERSITY OF TOLEDO (US) | 2024-03-21 | — | — | US | disclosed |
| US-11926631-B2 | Method of treating cancer using amanitin derivatives | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2024-03-12 | — | — | US | disclosed |
| CN-117683021-A | PD-1/PD-L1 pathway targeting compound and nuclide marker, preparation and application thereof | 厦门大学 | 2024-03-12 | — | — | CN | disclosed |
| CN-117580593-A | Anthracycline antibody conjugates | 思进公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-4021707-B1 | METHOD FOR MANUFACTURING A HOLEY FILM, IN PARTICULAR FOR ELECTRON MICROSCOPY APPLICATIONS | UNIV MUENSTER WESTFAELISCHE WILHELMS (DE) | 2023-10-04 | — | — | EP | disclosed |
| US-9328158-B2 | H. pylori lipopolysaccharide outer core epitope | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2016-05-03 | — | — | US | disclosed |
| CN-103623430-B | Preparation method and application of targeted co-supported drug delivery system nano-particles based on polylactic-co-glycolic acid | UNIV ZHENGZHOU | 2015-07-08 | — | — | CN | disclosed |
| US-20150087599-A1 | Peptide-Conjugated Oligonucleotide Therapeutic and Method of Making and Using Same | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2015-03-26 | — | — | US | disclosed |
| US-8895701-B2 | Peptide-conjugated oligonucleotide therapeutic and method of making and using same | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-11-25 | — | — | US | disclosed |
| CN-103623430-A | Preparation method and application of targeted co-supported drug delivery system nano-particles based on polylactic-co-glycolic acid | UNIV ZHENGZHOU | 2014-03-12 | — | — | CN | disclosed |
| US-20120301480-A1 | H. PYLORI LIPOPOLYSACCHARIDE OUTER CORE EPITOPE | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2012-11-29 | — | — | US | disclosed |
| US-20110003754-A1 | Peptide-Conjugated Oligonucleotide Therapeutic and Method of Making and Using Same | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-01-06 | — | — | US | disclosed |
| WO-2009066080-A2 | ARRAY | NANOBIODESIGN LIMITED (GB) | 2009-05-28 | — | — | WO | disclosed |
| US-7521232-B2 | Emissive species for clinical imaging | ICX NOMADICS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20070281289-A1 | Emissive species for clinical imaging | NOMADICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120301480-A1 | H. PYLORI LIPOPOLYSACCHARIDE OUTER CORE EPITOPE | DDOST, LY96, LY6K | PTGS1 566/4885PTGS2 817/4885ALDH1A1 3480/4885 |
| US-20240092932-A1 | MONOCLONAL IGM ANTIBODIES FROM ENTIRELY CARBOHYDRATE CONSTRUCTS | FCGR3B, FCGRT, FCGR2A | PTGS1 4321/4885PTGS2 4099/4885ALDH1A1 4474/4885 |
| US-11926631-B2 | Method of treating cancer using amanitin derivatives | ANXA5, AADAT, ANXA3 | PTGS1 4151/4885PTGS2 3984/4885ALDH1A1 2342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.